Understanding the tissue-specific genetic architecture of protein levels is instrumental to understand the biology of health and disease.

Join Prof. Matthew Johnson, PhD, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine as he explores how psychedelics may be leveraged in the treatment of a variety of nominally distinct psychiatric disorders.

Psychedelics have been used for millennia in both spiritual and medicinal contexts. Recently, a number of clinical successes with psychedelics have generated considerable excitement; nevertheless, mechanisms underlying their therapeutic efficacy are largely unknown.

In this webinar, we will summarise the current literature on non-invasive VNS in Parkinson’s disease and discuss preliminary findings of its therapeutic potential with an emphasis on its efficacy in improving cognitive and gait control in people with Parkinson’s.

In this session, Pall Corporation and Evello International will share their best practices on how to optimize your extraction and filtration process.

In this presentation, Cosmo Feilding-Mellen, co-founder and chief executive of Oxford-based psychedelic medicine company Beckley Psytech will take stock of the current psychedelic innovation landscape and the vast potential for psychedelic treatments in healthcare.